Mixed Peptoid Synthesis for Antibacterial Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current antibiotic compounds face challenges due to increasing drug resistance and poor pharmacokinetic properties of peptide-based drugs, such as stability, membrane permeability, bioavailability, and water solubility, limiting their effectiveness and leading to adverse side effects.

Innovation Solution

The development of a method to synthesize mixed peptoids containing lysine and arginine type monomers, using orthogonal protecting groups like Dde and Boc, allows for the creation of linear and cyclic peptoids with aromatic side chains, enhancing biological activity and stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If peptide-based drugs are used to combat infections, then biological activity is achieved, but stability and pharmacokinetic properties deteriorate

Engineering Contradiction:
Improvebiological activityVSAvoidstability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of peptides to create peptoids - specifically, moving side chains from the alpha-carbon to the nitrogen atom of the backbone. This structural parameter change confers proteolytic stability while maintaining biological activity, resolving the contradiction between activity and stability

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates composite peptoid structures incorporating both lysine-type (amine) and arginine-type (guanidinium) monomers in specific sequences. This composite approach combines the benefits of different side chain functionalities to achieve both stability and enhanced biological activity

Inventive Principle:
Principle #40Composite materials

2Quantity of substance

If peptides are formulated with excipients, surfactants and co-solvents to improve water solubility, then water solubility is improved, but adverse side effects increase

Engineering Contradiction:
Improvewater solubilityVSAvoidadverse side effects
Core Design Contradiction:
Quantity of substanceVSObject-generated harmful factors

Solution Approach 1:

The patent modifies the chemical parameters of the peptoid structure by incorporating aromatic side chains and balancing cationic (lysine/arginine) with hydrophobic residues. This intrinsic structural modification improves water solubility without requiring external excipients, thereby avoiding adverse side effects

Inventive Principle:
Principle #35Parameter changes

3Speed

If all lysine-type chains are transformed into arginine-type chains to improve cell penetration, then cell penetration is improved, but sequence diversity is reduced

Engineering Contradiction:
Improvecell penetrationVSAvoidsequence diversity
Core Design Contradiction:
SpeedVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by selectively transforming only specific lysine-type chains to arginine-type chains at predetermined positions in the peptoid sequence, while leaving other lysine-type chains unchanged. This localized modification maintains sequence diversity and allows optimization of cell penetration at specific locations without compromising overall versatility

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent segments the peptoid sequence into distinct regions with different functionalities - some segments contain arginine-type monomers for cell penetration, while other segments retain lysine-type monomers for structural diversity. This segmentation allows independent optimization of different functional requirements

Inventive Principle:
Principle #1Segmentation

Data Source

PatentEP3328877B1peptoid
Publication Date: 2022.08.24 UNIVERSITY OF DURHAM
  • EP3328877B1 patent drawingFigure 1~3A
  • EP3328877B1 patent drawingFigure 3B~4
  • EP3328877B1 patent drawingFigure 5

AI summary

The invention relates to peptoids, derivatives and analogues thereof, and to methods of chemically synthesising such compounds. The invention relates to mixed peptoids, derivatives and analogues thereof comprising lysine and arginine type monomers, which may be linear or cyclic, and to their uses in therapy, for example as antimicrobial agents, and in methods for treating microbial infections.